Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Physicians who Treat Stevens-Johnson Syndrome (US)

Council Members in this Study Group: 15

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITYSunil Dhawan, MD

Clinical Assistant Professor of Dermatology
STANFORD UNIVERSITY
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed care. Dr. Dhawan also runs the clinical trialdivision...

Barry Schechter, MD, Director of Corneal and External Diseases, FLORIDA EYE MICROSURGICAL INSTITUTE INCBarry Schechter, MD

Director of Corneal and External Diseases
FLORIDA EYE MICROSURGICAL INSTITUTE INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Barry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal, refractive, and cataract surgery, and glaucoma....

Ronald Innerfield, MD, Vice President of Clinical Affairs, Evidence Based Medicine, Inc.Ronald Innerfield, MD

Vice President of Clinical Affairs
Evidence Based Medicine, Inc.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Ronald Innerfield, MD, FACE, is Chief of Clinical Trials and Epidemiology, Emeritus, at the Dorothy Bullock Memorial National Diabetes Center. He is also Vice President of Clinical Affairs of Evidence Based Medicine, a site management organization (SMO) in Princeton. Dr. Innerfield was a primary medical...

Darcy Ryan, OD

Optometrist
Hertzog Eye Associates
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Darcy Ryan, OD, is an Optometrist at Hertzog Eye Associates, an Ophthalmological practice in Long Beach, California. He performs routine and specialty adult and pediatric eye exams. He treats and co-manages patients with almost every type of eye condition, including those with glaucoma, microbial infections,...

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Presta Trial shows good results for Enbrel

October 14, 2009

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY

New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com

This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy,...

Metanalyses, Metapsychoses

September 30, 2009

Ronald Innerfield, MD, Vice President of Clinical Affairs, Evidence Based Medicine, Inc.

Controls to blood sugar 'cuts stroke risk' | www.barchester.com

There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore,...

Will the withdrawl of Efalizumab effect the biologic market?

April 15, 2009

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY

Efalizumab withdrawn from US Market | www.medscape.com

This article is important in that the withdrawal of efalizumab by Genentech was appropriate in view of its serious side effect of progressive multifocal leukoencephalopathy (PML). This biologic agent was already declining in usage because of its other side effects, and the presence of other strongcompetitors...

Aurobindo terbinafine approval- what effect will this have?

January 21, 2009

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY

Aurobindo Pharma gets approval for Terbinafine Tablets | myiris.com

This article is important in that it confirms another terbinafine competitor to the Novartis Lamisil brand is being released. The majority of terbinafine prescriptions in North America are generic. The market for this product will be good at least until more effective oral or topical agents are released....

Filler Warnings- Are They Necessary?

November 24, 2008

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY

FDA Faults Wrinkle Fillers Over Warnings | online.wsj.com

This article is important in that it discusses a rare but known side effect of filler injections- reactions to these agents. These reactions include allergies, infections, etc. The incidence is low- approximately 1000 cases out of 1.5 million injections. The majority of these reactions were not serious....

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Contract Research Organization, Independent/Small
  • Non-Academic Community Hospital or Clinic
  • Research Foundation

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Physician - Department Chair
  • Project Manager
  • Vice President
  • Physician - Division Head
  • Allied Health Professional
  • Owner